Skip to Main content Skip to Navigation
New interface
Journal articles

The path towards herd immunity: Predicting COVID-19 vaccination uptake through results from a stated choice study across six continents

Stephane Hess 1 Emily Lancsar 2 Petr Mariel 3 Jürgen Meyerhoff 4 Fangqing Song 1, 5 Eline van den Broek-Altenburg 6 Olufunke Alaba 7 Gloria Amaris 1, 8 Julián Arellana 9 Leonardo Basso 10 Jamie Benson 6 Luis Bravo-Moncayo 11, 12 Olivier Chanel 13 Syngjoo Choi 14 Romain Crastes Dit Sourd 1 Helena Bettella Cybis 15 Zack Dorner 16 Paolo Falco 17 Luis Garzón-Pérez 12 Kathryn Glass 2 Luis Guzman 18 Zhiran Huang 19 Elisabeth Huynh 2 Bongseop Kim 14 Abisai Konstantinus 20 Iyaloo Konstantinus 21 Ana Margarita Larranaga 15 Alberto Longo 22 Becky P.Y. Loo 19 Malte Oehlmann 23 Vikki O'Neill 22 Juan de Dios Ortúzar 24 María José Sanz 25, 26 Olga Sarmiento 18 Hazvinei Tamuka Moyo 7 Steven Tucker 16 Yacan Wang 27 Yu Wang 27 Edward J.D. Webb 1 Junyi Zhang 28 Mark H.P. Zuidgeest 7 
Abstract : Despite unprecedented progress in developing COVID-19 vaccines, global vaccination levels needed to reach herd immunity remain a distant target, while new variants keep emerging. Obtaining near universal vaccine uptake relies on understanding and addressing vaccine resistance. Simple questions about vaccine acceptance however ignore that the vaccines being offered vary across countries and even population subgroups, and differ in terms of efficacy and side effects. By using advanced discrete choice models estimated on stated choice data collected in 18 countries/territories across six continents, we show a substantial influence of vaccine characteristics. Uptake increases if more efficacious vaccines (95% vs 60%) are offered (mean across study areas = 3.9%, range of 0.6%–8.1%) or if vaccines offer at least 12 months of protection (mean across study areas = 2.4%, range of 0.2%–5.8%), while an increase in severe side effects (from 0.001% to 0.01%) leads to reduced uptake (mean = −1.3%, range of −0.2% to −3.9%). Additionally, a large share of individuals (mean = 55.2%, range of 28%–75.8%) would delay vaccination by 3 months to obtain a more efficacious (95% vs 60%) vaccine, where this increases further if the low efficacy vaccine has a higher risk (0.01% instead of 0.001%) of severe side effects (mean = 65.9%, range of 41.4%–86.5%). Our work highlights that careful consideration of which vaccines to offer can be beneficial. In support of this, we provide an interactive tool to predict uptake in a country as a function of the vaccines being deployed, and also depending on the levels of infectiousness and severity of circulating variants of COVID-19.
Document type :
Journal articles
Complete list of metadata
Contributor : Elisabeth Lhuillier Connect in order to contact the contributor
Submitted on : Friday, September 16, 2022 - 9:08:34 AM
Last modification on : Wednesday, November 9, 2022 - 9:58:05 AM


Publication funded by an institution


Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License




Stephane Hess, Emily Lancsar, Petr Mariel, Jürgen Meyerhoff, Fangqing Song, et al.. The path towards herd immunity: Predicting COVID-19 vaccination uptake through results from a stated choice study across six continents. Social science & medicine, 2022, 298, pp.114800. ⟨10.1016/j.socscimed.2022.114800⟩. ⟨hal-03778395⟩



Record views


Files downloads